Neurobiology of opiate abuse

doi:10.1016/0165-6147(92)90062-B

Trends in Pharmacological Sciences

Volume 13, 1992, Pages 185-193

https://doi.org/10.1016/0165-6147(92)90062-B Get rights and content

Abstract

Opiates interact with cell surface receptors on neurons involved in the transmission of information along neural pathways that are related to behaviours essential for the life of the self and of the species. Opiates are provided with powerful and multifaceted rewarding properties that are fundamental for the acquisition, maintenance and relapse of opiate addiction. Gaetano Di Chiara and Alan North argue that both dopaminergic and nondopaminergic systems are involved in opiate reward, and that opiate addiction results from adaptive and learning processes involving both positive reinforcing mechanisms related to the rewarding properties of opiates and negative reinforcing mechanisms related to the aversive properties of withdrawal in dependent subjects.

References (69)

S.R. Childers
Life Sci.
(1991)
G.K. Aghajanian et al.
Brain Res.
(1986)
X. Guitart et al.
Brain Res.
(1990)
T.L. Wimpey et al.
Neuron
(1991)
E.J. Nestler et al.
Brain Res.
(1989)
R.V. Esposito et al.
Neurosci. Biobehav. Rev.
(1978)
C.L. Broekkamp et al.
Pharmacol. Biochem. Behav.
(1979)
A.C. Phillips et al.
Pharmacol. Biochem. Behav.
(1980)
M.A. Bozarth et al.
Life Sci.
(1981)
H. Welzl et al.
Neuropharmacology
(1989)

M. Carballo et al.

Global Program on AIDS

WHO report

(1989)

H.H. Loh et al.

Annu. Rev. Toxicol.

(1990)

H. Ueda et al.

Comp. Biochem. Physiol.

(1991)

H.G. Dohlman et al.

Biochemistry

(1987)

J.A.H. Lord et al.

Nature

(1977)

Cited by (493)

Striatal μ-opioid receptor activation triggers direct-pathway GABAergic plasticity and induces negative affect
2023, Cell Reports
Withdrawal from chronic opioid use often causes hypodopaminergic states and negative affect, which may drive relapse. Direct-pathway medium spiny neurons (dMSNs) in the striatal patch compartment contain μ-opioid receptors (MORs). It remains unclear how chronic opioid exposure and withdrawal impact these MOR-expressing dMSNs and their outputs. Here, we report that MOR activation acutely suppressed GABAergic striatopallidal transmission in habenula-projecting globus pallidus neurons. Notably, withdrawal from repeated morphine or fentanyl administration potentiated this GABAergic transmission. Furthermore, intravenous fentanyl self-administration enhanced GABAergic striatonigral transmission and reduced midbrain dopaminergic activity. Fentanyl-activated striatal neurons mediated contextual memory retrieval required for conditioned place preference tests. Importantly, chemogenetic inhibition of striatal MOR⁺ neurons rescued fentanyl withdrawal-induced physical symptoms and anxiety-like behaviors. These data suggest that chronic opioid use triggers GABAergic striatopallidal and striatonigral plasticity to induce a hypodopaminergic state, which may promote negative emotions and relapse.
Effects of the selective dopamine D<inf>3</inf> receptor antagonist PG01037 on morphine-induced hyperactivity and antinociception in mice
2021, Behavioural Brain Research
Citation Excerpt :
The D1-like receptor family includes the Gs-coupled D1 and D5 receptor subtypes (D1R and D5R) while the D2-like receptor family includes the Gi-coupled D2, D3, and D4 receptor subtypes (D2R, D3R, D4R) [24]. Administration of nonselective antagonists at either D1-like receptors or D2-like receptors reduces opioid-induced locomotor activation, opioid self-administration, and opioid seeking [for review, see 4–6,25]. However, adverse side effects (e.g., extrapyramidal effects, hyperprolactinemia, somnolence, effects on blood pressure), poor retention rates, and/or loss of efficacy following chronic administration have hindered the potential clinical utility of these drug classes as treatments for substance use disorders [26–30].
Recent preclinical studies have reported that pretreatment with the novel and highly-selective dopamine D₃ receptor (D₃R) antagonists R-VK4-40 or VK4-116 attenuates the abuse-related behavioral effects of oxycodone while enhancing its analgesic properties. However, whether these observed effects are generalizable to the broad class of D₃R antagonists and/or extend to opioids other than oxycodone has not been extensively explored. The present study sought to assess the impact of pretreatment with another selective D₃R antagonist, PG01037, on several behavioral effects of morphine in mice. C57Bl/6 J mice were pretreated with PG01037 (0–10 mg/kg) and tested for 1) hyperlocomotion induced by acute morphine (5.6–56 mg/kg), 2) locomotor sensitization following repeated morphine (56 mg/kg), 3) antinociception following acute morphine (18 mg/kg), and 4) catalepsy following administration of PG01037 alone or in combination with morphine (56 mg/kg). PG01037 dose-dependently attenuated morphine-induced hyperlocomotion and morphine-induced antinociception at doses that did not alter basal locomotion or nociception alone, but did not prevent the induction of locomotor sensitization following repeated morphine administration. Moreover, PG01037 did not induce catalepsy either alone or in combination with morphine. These results suggest that attenuation of acute opioid-induced hyperactivity may be a behavioral effect shared among D₃R-selective antagonists, thus supporting continued investigations into their use as potential treatments for opioid use disorder. However, PG01037 is unlike newer, highly-selective D₃R antagonists in its capacity to reduce opioid-induced antinociception, indicating that modulation of opioid analgesia may vary across different D₃R antagonists.
Heightened healthcare utilization & risk of mental disorders among Veterans with comorbid opioid use disorder & posttraumatic stress disorder
2021, Addictive Behaviors
Although Veterans with posttraumatic stress disorder (PTSD) are vulnerable to opioid misuse, there is limited research evaluating the psychosocial and medical sequalae experienced by Veterans with comorbid PTSD and opioid use disorder (OUD). Using data from a nationwide, longitudinal registry of Operation Enduring Freedom/Operation Iraqi Freedom/Operation New Dawn (OEF/OIF/OND) Veterans oversampled for PTSD with a 1:1 ratio of men to women, we identified Veterans with lifetime diagnoses of comorbid PTSD and OUD (n = 40), PTSD and non-opioid substance use disorder (SUD; n = 386), PTSD only (n = 901), and non-opioid SUD only (n = 52) using medical record data. We then compared these groups on Veterans Affairs emergency, urgent care, and inpatient healthcare utilization, suicide risk, functional impairment, and the presence of comorbid mental conditions in the following 1–2 years. Relative to all other groups, Veterans with comorbid OUD and PTSD had increased likelihood of emergency room and inpatient care, probable somatoform and major depressive disorders, and greater functional impairment. Both the PTSD/OUD group and PTSD/non-opioid SUD group demonstrated increased suicidality, urgent care utilization, and probable generalized anxiety disorder relative to Veterans with PTSD only or non-opioid SUD only. Results suggest that comorbid OUD and PTSD are associated with greater likelihood of negative psychiatric and healthcare related outcomes, even relative to PTSD comorbid with other types of SUDs. Findings support the importance of concentrated and sustained efforts to improve prevention and intervention strategies for Veterans struggling with PTSD symptoms and opioid misuse.
Drug instrumentalization
2020, Behavioural Brain Research
Psychoactive drugs with addiction potential are widely used by people of virtually all cultures in a non-addictive way. In order to understand this behaviour, its population penetrance, and its persistence, drug instrumentalization was suggested as a driving force for this consumption. Drug instrumentalization theory holds that psychoactive drugs are consumed in a very systematic way in order to make other, non-drug-related behaviours more efficient. Here, we review the evolutionary origin of this behaviour and its psychological mechanisms and explore the neurobiological and neuropharmacological mechanisms underlying them. Instrumentalization goals are discussed, for which an environmentally selective and mental state-dependent consumption of psychoactive drugs can be learned and maintained in a non-addictive way. A small percentage of people who regularly instrumentalize psychoactive drugs make a transition to addiction, which often starts with qualitative and quantitative changes in the instrumentalization goals. As such, addiction is proposed to develop from previously established long-term drug instrumentalization. Thus, preventing and treating drug addiction in an individualized medicine approach may essentially require understanding and supporting personal instrumentalization goals.
Non-pharmacological factors that determine drug use and addiction
2020, Neuroscience and Biobehavioral Reviews
Based on their pharmacological properties, psychoactive drugs are supposed to take control of the natural reward system to finally drive compulsory drug seeking and consumption. However, psychoactive drugs are not used in an arbitrary way as pure pharmacological reinforcement would suggest, but rather in a highly specific manner depending on non-pharmacological factors. While pharmacological effects of psychoactive drugs are well studied, neurobiological mechanisms of non-pharmacological factors are less well understood. Here we review the emerging neurobiological mechanisms beyond pharmacological reinforcement which determine drug effects and use frequency. Important progress was made on the understanding of how the character of an environment and social stress determine drug self-administration. This is expanded by new evidence on how behavioral alternatives and opportunities for drug instrumentalization generate different patterns of drug choice. Emerging evidence suggests that the neurobiology of non-pharmacological factors strongly determines pharmacological and behavioral drug action and may, thus, give rise for an expanded system’s approach of psychoactive drug use and addiction.
A novel neurobehavioral framework of the effects of positive early postnatal experience on incentive and consummatory reward sensitivity
2019, Neuroscience and Biobehavioral Reviews
Early postnatal experience has a profound influence on the development of organisms. In this integration, we provide a novel framework of the neurobehavioral pathways through which positive early postnatal experience acts to enhance adult reward sensitivity. The heterogeneity of the construct of reward and the underlying neurotransmitter systems (i.e., dopamine in incentive reward, opioids in consummatory reward, and oxytocin in orienting the reward systems to social cues) are first described as a means of organizing the discussion. Then, for each neurotransmitter system, their early postnatal ontogenesis is depicted for identifying potential sensitive periods for the effects of early experience. This is followed by the presentation of a model of the neurobehavioral foundation of two main forms of positive early postnatal experience that, with their essential components – novelty and positive tactile stimulation, facilitate the development of incentive and consummatory reward systems. Next, a detailed analysis of the major effects of positive early prewean and postwean experience on the neural and behavioral functioning of each neurotransmitter system is reviewed. The data support the neurobehavioral model presented, which theorizes that essential components of positive early experience enhance incentive and consummatory reward sensitivities through early activation of particular neural pathways. These activity-dependent effects are sustained via structural modifications of underlying neural circuitries.

View all citing articles on Scopus

View full text

Trends in Pharmacological Sciences

Neurobiology of opiate abuse

Abstract

Life Sci.

Brain Res.

Brain Res.

Neuron

Brain Res.

Neurosci. Biobehav. Rev.

Pharmacol. Biochem. Behav.

Pharmacol. Biochem. Behav.

Life Sci.

Neuropharmacology

Pharmacol. Biochem. Behav.

Brain Res.

Pharmacol. Biochem. Behav.

Brain Res.

Life Sci.

Eur. J. Pharmacol.

Brain Res.

Pharmacol. Biochem. Behav.

Pharmacol. Biochem. Behav.

Pharmacol. Biochem. Behav.

Brain Res.

Brain Res.

Pharmacol. Biochem. Behav.

Neuropharmacology

Brain Res.

Brain Res.

Pharmacol. Biochem. Behav.

Eur. J. Pharmacol.

Global Program on AIDS

WHO report

Annu. Rev. Toxicol.

Comp. Biochem. Physiol.

Biochemistry

Nature